Focused Ultrasound: Breaking Barriers

Healthcare

September 12, 2024 – Stifel IRIS is pleased to release “Focused Ultrasound: breaking barriers in drug delivery, brain therapy and beyond”, a white paper which offers an extensive analysis of the evolving role that ultrasounds play in contemporary healthcare, with recent technological advancements extending its capabilities far beyond its conventional applications.

While High-Intensity Focused Ultrasound (HIFU) has been a mainstay for over 30 years, recent breakthroughs in low- to medium-energy nonthermal ultrasound are presenting groundbreaking opportunities. These emerging technologies provide innovative alternatives or complements to conventional treatments such as surgery, drug delivery, radiation therapy, chemotherapy, and cancer immunotherapy, making them pivotal in modern healthcare.

The focused ultrasound market is experiencing significant growth at a 22% CAGR, to reach EUR 1 billion by 2029. This surge is driven by companies approaching the final stages of clinical validation, alongside robust support from established MedTech and Pharma firms providing financial and strategic backing. These include GE Healthcare, Novo Nordisk, Johnson & Jonhson, among others.

In this white paper, we provide an in-depth look at the most critical developments within this sector and identify key innovators shaping the future of ultrasound technologies.